Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Com Stk Usd0.01 [Di/Reg S] (MXCN.LN)

Com Stk Usd0.01 [Di/Reg S] (MXCN.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 436,621
  • Shares Outstanding, K 100,434
  • Annual Sales, $ 41,288 K
  • Annual Income, $ -37,923 K
  • 60-Month Beta N/A
  • Price/Sales 24.19
  • Price/Cash Flow N/A
  • Price/Book 3.50
Trade MXCN.LN with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.19
  • Most Recent Earnings $-0.03 on N/A
  • Latest Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
680.000 unch
on 02/24/22
775.000 -12.26%
on 02/04/22
-95.000 (-12.26%)
since 01/24/22
3-Month
680.000 unch
on 02/24/22
800.000 -15.00%
on 11/30/21
-120.000 (-15.00%)
since 11/24/21
52-Week
680.000 unch
on 02/24/22
1,025.000 -33.66%
on 10/05/21
-270.000 (-28.42%)
since 02/24/21

Most Recent Stories

More News
MaxCyte Reports Second Quarter and Half-Year 2022 Financial Results

45% Year-Over-Year Core Business Revenue Growth in Second Quarter 2022 Raises 2022 Core Revenue Growth Guidance to Approximately 30% ROCKVILLE, Md.,...

MXCT : 3.88 (-3.00%)
MXCN.LN : 680.000 (unch)
MXCT.LN : 315.000 (-2.64%)
MaxCyte to Report Second Quarter 2022 Financial Results on August 10, 2022

GAITHERSBURG, Md., July 15, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on...

MXCT : 3.88 (-3.00%)
MXCN.LN : 680.000 (unch)
MXCT.LN : 315.000 (-2.64%)
MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GAITHERSBURG, Md., May 13, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on...

MXCT : 3.88 (-3.00%)
MXCN.LN : 680.000 (unch)
MXCT.LN : 315.000 (-2.64%)
MaxCyte Reports First Quarter Financial Results

MaxCyte Increases 2022 Core Revenue Growth Guidance to be at least 25% and Reiterates Milestone Revenue Guidance of $4 million...

MXCT : 3.88 (-3.00%)
MXCN.LN : 680.000 (unch)
MXCT.LN : 315.000 (-2.64%)
MaxCyte to Participate in Upcoming Investor Conferences

GAITHERSBURG, Md., May 03, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on...

MXCT : 3.88 (-3.00%)
MXCN.LN : 680.000 (unch)
MXCT.LN : 315.000 (-2.64%)
MaxCyte to Report First Quarter 2022 Financial Results on May 9, 2022

GAITHERSBURG, Md., April 20, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on...

MXCT : 3.88 (-3.00%)
MXCN.LN : 680.000 (unch)
MXCT.LN : 315.000 (-2.64%)
MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GAITHERSBURG, Md., April 15, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company...

MXCT : 3.88 (-3.00%)
MXCN.LN : 680.000 (unch)
MXCT.LN : 315.000 (-2.64%)
MaxCyte Announces Departure of CFO and Appointment of Ron Holtz as Interim CFO, Announces Preliminary First Quarter 2022 Revenue

GAITHERSBURG, Md., April 12, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on...

MXCT : 3.88 (-3.00%)
MXCN.LN : 680.000 (unch)
MXCT.LN : 315.000 (-2.64%)
MaxCyte Reports Fourth Quarter and Full Year Financial Results

MaxCyte Provides Initial 2022 Guidance...

MXCT : 3.88 (-3.00%)
MXCN.LN : 680.000 (unch)
MXCT.LN : 315.000 (-2.64%)
MaxCyte, Inc. Names Cenk Sumen Chief Scientific Officer

Dr. Sumen brings extensive experience in scientific and technology evaluation, process development and leadership....

MXCT : 3.88 (-3.00%)
MXCN.LN : 680.000 (unch)
MXCT.LN : 315.000 (-2.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 680.000
2nd Resistance Point 680.000
1st Resistance Point 680.000
Last Price 680.000
1st Support Level 680.000
2nd Support Level 680.000
3rd Support Level 680.000

See More

52-Week High 1,025.000
Fibonacci 61.8% 893.210
Fibonacci 50% 852.500
Fibonacci 38.2% 811.790
Last Price 680.000
52-Week Low 680.000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar